About Us

Stelexis Therapeutics is committed to transforming cancer treatment through the discovery of novel targets aimed at the tumor’s origin. Pre-cancer and cancer stem cells (cancerous stem cells) are a primary cause of cancer progression and relapse, and they’re typically not eliminated by current treatment approaches. Previously, identifying targets on cancerous stem cells was almost impossible due to difficulties isolating, propagating and maintaining clinically relevant stem cells for research. Aided by seminal discoveries at leading academic institutions, the Company has developed a proprietary platform, called TumorOrigin™, which enables unprecedented study of these cells for drug discovery.

Our Approach

The TumorOrigin™ platform is designed to discover novel, druggable targets on cancerous stem cells. Utilizing large banks of patient-derived samples, this proprietary approach isolates, expands and maintains these rare cells. The platform is also capable of overcoming former limitations, such as insufficient cell count and cell survival, which until now impeded this area of cancer research.